You are viewing: Latin America Minimal Residual Disease Market analysis

The Latin America Minimal Residual Disease Market was valued at $51.6 Million in 2024 and projected to reach to $88.8 Million by 2029, representing a compound annual growth rate of 11.5%. Latin America's Minimal Residual Disease market is positioned for sustained expansion through 2029, driven by convergence of clinical demand and infrastructure development.

Latin America Minimal Residual Disease Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Latin America Minimal Residual Disease Market Trends and Insights

  • Latin America's MRD market growth is driven by increasing adoption of advanced diagnostic technologies, rising cancer incidence rates, and expanding healthcare infrastructure across the region.
  • In Latin America, the 11.5% compound annual growth rate reflects growing investment in precision oncology and improved access to molecular testing platforms that enable early detection of residual disease in cancer patients. Latin America's healthcare systems are increasingly recognizing the clinical and economic value of MRD monitoring in treatment decision-making and patient outcomes.
  • The forecast period through 2029 demonstrates Latin America's commitment to modernizing cancer care through enhanced diagnostic capabilities.
  • In Latin America, key market drivers include regulatory support for companion diagnostics, rising healthcare expenditure, and growing collaboration between regional laboratories and international diagnostic providers..

Key Market Statistics

  • CAGR (2024-2029) 11.5% CAGR
  • Market Size, 2024 ~USD 51.6 Million
  • Forecast, 2029 ~USD 88.8 Million
  • Geography Latin America

Latin America Minimal Residual Disease Market Overview

Market Valuation & Growth :

Latin America's MRD market is valued at $51.6 million in 2024, with a robust 11.5% CAGR projected through 2029, reaching $88.8 million. This growth trajectory reflects strong regional momentum in precision oncology diagnostics.

Rising Cancer Incidence :

Increasing cancer prevalence across Latin America is driving demand for early detection and monitoring solutions. MRD testing enables clinicians to identify residual disease post-treatment, improving patient outcomes and treatment personalization.

Healthcare Infrastructure Expansion :

Latin American countries are investing in advanced diagnostic capabilities and laboratory infrastructure. This modernization supports adoption of sophisticated MRD technologies and expands access to precision medicine across the region.

Technology Adoption Acceleration :

Growing adoption of next-generation sequencing, digital PCR, and flow cytometry platforms in Latin American healthcare facilities is accelerating MRD market penetration. Regional laboratories are increasingly integrating these advanced diagnostic methods into clinical practice.

Latin America Minimal Residual Disease Market Dynamics

  • Healthcare providers across the region are recognizing MRD testing's critical role in optimizing cancer treatment protocols and improving patient survival rates.
  • Increasing investment in oncology centers and diagnostic laboratories, coupled with rising awareness among physicians and patients, will fuel market growth. The region's MRD market will benefit from improving reimbursement policies, growing partnerships between local healthcare systems and international diagnostic companies, and enhanced access to training programs.
  • As Latin American countries strengthen their precision medicine capabilities, MRD adoption will expand beyond major metropolitan centers into secondary and tertiary care facilities, creating significant growth opportunities for market participants..

Related Ecosystem

Analytical And Scientific Instrumentation

Top Technologies
  • Environmental Testing
  • Gas Chromatography
  • Polymerase Chain Reaction (PCR)
  • Automated Liquid Handling Systems
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Shimadzu Corporation
  • Merck KGaA

    Diagnostic Imaging

    Top Technologies
    • Magnetic Resonance Imaging (MRI)
    • Computed Tomography (CT)
    • CT Scanners
    • Nuclear Imaging
    • Positron Emission Tomography
    Top Companies
    • Siemens healthineers
    • PHILIPS HEALTHCARE
    • CANON INC.
    • FUJIFILM Holdings Corporation
    • UNITED IMAGING HEALTHCARE CO., LTD.

      In Vitro Diagnostics

      Top Technologies
      • Polymerase Chain Reaction (PCR)
      • Enzyme-Linked Immunosorbent Assay (ELISA)
      • Dna Microarrays
      • Assay Kits
      • Microarrays
      Top Companies
      • ROCHE HOLDINGS AG
      • Thermo Fisher Scientific Inc.
      • Danaher Corporation
      • Abbott Laboratories
      • Biomerieux s.a.

        Key Takeaways

        • Latin America's MRD market is valued at $51.6 million in 2024 and expected to grow to $88.8 million by 2029, representing a 11.5% CAGR.
        • Latin America is witnessing increased adoption of precision oncology and molecular diagnostic technologies for early cancer detection and treatment monitoring.
        • Latin America's healthcare infrastructure expansion and regulatory support for companion diagnostics are accelerating MRD market penetration across the region.
        • Latin America's growing collaboration between regional laboratories and international diagnostic providers is enhancing access to advanced MRD testing capabilities.

        Minimal Residual Disease Market Report Scope

        Report Metric Details
        Base Year 2024
        Fastest Growing Segment MULTIPLE MYELOMA (Application)
        Forecast Period 2024-2029
        Growth Rate CAGR of 12.2% from 2024 to 2029
        Largest Segment ASSAY KITS & REAGENTS (Product)
        Market Size Base Year (Billions) ~USD 1.43 (2024)
        Revenue Forecast (Billions) ~USD 2.55 (2029)
        Segments Covered Product, Technology, Application, Type, End User

        Latin America Minimal Residual Disease Market Report Segmentation

        5 segment dimensions are covered across the global market.

        By Product

        • Assay Kits & Reagents
        • Instruments

        By Technology

        • Flow Cytometry
        • Next-Generation Sequencing
        • Other Technologies
        • Polymerase Chain Reaction

        By Application

        • Hematological Malignancies
        • Multiple Myeloma
        • Other Applications
        • Solid Tumors

        By Type

        • Hodgkin Lymphoma
        • Leukemia
        • Lymphoblastic Leukemia
        • Lymphocytic Leukemia
        • Lymphoma
        • Myeloid Leukemia
        • Non-Hodgkin Lymphoma
        • Other Leukemias

        By End User

        • Academic & Research Institutes
        • Diagnostic Laboratories
        • Hospitals & Specialty Clinics
        • Other End Users

        Target Audience

        • Diagnostic Device Manufacturers : Evaluate Latin America as a strategic expansion market for MRD testing platforms. Understand regional demand, competitive positioning, and regulatory pathways to optimize product launches and market penetration strategies.
        • Healthcare System Administrators : Assess MRD technology adoption requirements and budget allocation for oncology programs. Benchmark regional capabilities against international standards and identify infrastructure investments needed to support precision medicine initiatives.
        • Pharmaceutical & Biotech Companies : Leverage MRD market insights to support clinical trial design, patient stratification, and treatment monitoring strategies in Latin America. Understand regional adoption barriers and opportunities for companion diagnostic integration.
        • Investment & Private Equity Firms : Identify high-growth investment opportunities in Latin American diagnostic companies and healthcare infrastructure. Evaluate market dynamics, competitive positioning, and exit potential within the expanding MRD sector.
        • Clinical Laboratory Operators : Understand market demand for MRD testing services and competitive dynamics across Latin America. Identify technology partnerships, service expansion opportunities, and reimbursement models to enhance laboratory profitability.

        Latin America vs. other regions

        HowLatin America compares to the other 3 regional blocs covered in this market.

        North America
        ~USD 789.9 Million · 13.2% wtd CAGR ·
        Europe
        ~USD 450.5 Million · 12.5% wtd CAGR ·
        Asia Pacific
        ~USD 396 Million · 14.3% wtd CAGR ·
        Middle East & Africa
        ~USD 61.7 Million · 10.2% wtd CAGR ·

        Countries within Latin America - compare and drill down

        Country2025 size (native)

        Country market size visualization

        Reasons to Buy this Report

        • Regional Market Sizing & Forecasts : Obtain precise market valuations for Latin America's MRD sector with detailed 2024-2029 projections. Understand regional growth dynamics distinct from global trends and identify expansion opportunities within this high-growth geography.
        • Competitive Landscape Analysis : Gain insights into key players, market share distribution, and competitive strategies specific to Latin America. Identify partnership opportunities, acquisition targets, and gaps in regional service delivery.
        • Country-Level Granularity : Access market data segmented by individual Latin American countries, enabling targeted market entry strategies. Understand country-specific regulatory environments, reimbursement policies, and healthcare infrastructure maturity.
        • Growth Driver Identification : Understand the specific factors accelerating MRD adoption in Latin America—rising cancer rates, infrastructure investments, and technology adoption patterns. Leverage these insights for strategic planning and resource allocation.
        • Investment & Expansion Strategy : Make informed decisions on market entry, partnership development, and product localization for Latin America. Benchmark regional performance against global standards and identify high-potential sub-markets for prioritized investment.

        Frequently asked questions

        What is the current market size of MRD testing in Latin America?

        In Latin America, the Minimal Residual Disease market was valued at $51.6 million in 2024 and is projected to reach $88.8 million by 2029.

        What is the expected growth rate for MRD market in Latin America?

        Latin America's MRD market is expected to grow at a compound annual growth rate (CAGR) of 11.5% from 2024 to 2029.

        What factors are driving MRD market growth in Latin America?

        Latin America's MRD market growth is driven by increasing cancer incidence, adoption of precision oncology, expanding healthcare infrastructure, regulatory support for diagnostics, and rising healthcare expenditure.

        Which cancer types benefit most from MRD testing in Latin America?

        In Latin America, MRD testing is primarily utilized in hematologic malignancies such as acute leukemia and lymphoma, as well as solid tumors including breast and colorectal cancers.

        How is Latin America's healthcare system supporting MRD adoption?

        Latin America's healthcare systems are supporting MRD adoption through regulatory frameworks for companion diagnostics, increased healthcare investment, and partnerships between regional and international diagnostic providers.

        RESEARCH METHODOLOGY

        This study involved four major activities in estimating the current size of the minimal residual disease testing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

        Secondary Research

        In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

        Primary Research

        In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.

        The following is a breakdown of the primary respondents:

        Minimal Residual Disease Market

        Note 1: Others include sales managers, marketing managers, and product managers.

        Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

        To know about the assumptions considered for the study, download the pdf brochure

        COMPANY NAME DESIGNATION
        Roche Ltd. General Manager
        Gaurdant Area Sales Manager

        Market Size Estimation

        Both top-down and bottom-up approaches were used to estimate and validate the minimal residual disease testing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

        • The key players in the industry have been identified through extensive secondary research
        • The revenues generated by leading players operating in the minimal residual disease testing market have been determined through primary and secondary research
        • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

        The research methodology used to estimate the market size includes the following:

        Minimal Residual Disease Market

        Data Triangulation

        After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

        Market Definition

        Minimal Residual Disease (MRD) refers to the small number of cancer cells left in a body after cancer treatment. MRD tests are performed to diagnose and monitor patients with various hematology cancers, such as leukemia, lymphoma, and myeloma. An MRD test looks for cancer cells not killed by chemotherapy or other cancer treatments. Moreover, these tests also play a crucial role in clinical trials of hemato-oncology therapeutics.

        Stakeholders

        • Senior Management
        • End User
        • Finance/Procurement Department 
        • R&D Department

        Report Objectives

        • To define, describe, segment, and forecast the global minimal residual disease testing market by product, technology, application, end user, and region
        • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
        • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall minimal residual disease testing market
        • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
        • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
        • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
        • To track and analyze company developments such as product launches, agreements, partnerships, and acquisitions in the minimal residual disease testing market
        • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

         

        Get the Full Minimal Residual Disease Market Report

        Full forecast, segment splits, and company analysis for all Minimal Residual Disease Market.

        Need a Tailored Report?

        Customize this report to your needs

        Get 10% FREE Customization

        Customize This Report
        Fact checked
        DMCA.com Protection Status